2017
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medication
2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
2007
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings
Epperson CN, Amin Z, Naftolin F, Cappiello A, Czarkowski KA, Stiklus S, Anderson GM, Krystal JH. The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings. Journal Of Psychopharmacology 2007, 21: 414-420. PMID: 16891341, DOI: 10.1177/0269881106067330.Peer-Reviewed Original ResearchConceptsMenopausal womenTryptophan depletionSelective serotonin reuptake inhibitor fluoxetineAcute tryptophan depletion paradigmSerotonin reuptake inhibitor fluoxetineTryptophan depletion paradigmPathogenesis of depressionReuptake inhibitor fluoxetineMajor depressive episodeAcute tryptophan depletionRelapse of depressionWorsening of moodWeeks of recoveryActive tryptophan depletionWechsler Memory ScaleAssessment of moodDepressive episodeRisk factorsDepressive relapseMajor depressionSignificant worseningNeuroendocrine functionVerbal memorySerotonergic contributionMemory Scale
1999
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action
Delgado P, Miller H, Salomon R, Licinio J, Krystal J, Moreno F, Heninger G, Charney D. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry 1999, 46: 212-220. PMID: 10418696, DOI: 10.1016/s0006-3223(99)00014-1.Peer-Reviewed Original ResearchConceptsTRP depletionAntidepressant responseDepressed patientsSuccessful antidepressant treatmentBrain serotonin contentSignificant depressive symptomsAmino acid drinkRole of serotoninMonoamine oxidase inhibitorsRelationship of relapseAntidepressant actionAntidepressant treatmentReuptake inhibitorsPlasma tryptophanPlasma levelsAntidepressant typeTherapeutic responseDepressive relapseSerotonin contentTherapeutic effectTRP levelsDepressive symptomsTreatment phasePatientsAcid drink
1996
Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression
Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS. Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression. JAMA Psychiatry 1996, 53: 117-128. PMID: 8629887, DOI: 10.1001/archpsyc.1996.01830020031005.Peer-Reviewed Original ResearchConceptsNorepinephrine reuptake inhibitorsReuptake inhibitorsCatecholamine depletionAlpha-methylparatyrosineTreatment groupsHamilton Depression Rating ScaleHomovanillic acid levelsSerotonin reuptake inhibitorsDepression Rating ScaleSimilar significant decreaseAntihistamine diphenhydramine hydrochlorideSeparate test sessionsFeelings of worthlessnessConsiderable sedationLoss of interestDepressed patientsDepressive relapseAntidepressant drugsInactive placeboTherapeutic effectTherapeutic mechanismDepressive symptomsCatecholamine metabolitesPlasma 3Remission
1994
Precipitation of a Psychoneuromotor Syndrome by Fluoxetine in a Haloperidol-
D'SOUZA D, BENNETT A, ABI-DARGHAM A, KRYSTAL J. Precipitation of a Psychoneuromotor Syndrome by Fluoxetine in a Haloperidol-. Journal Of Clinical Psychopharmacology 1994, 14: 361-362. PMID: 7806697, DOI: 10.1097/00004714-199410000-00018.Peer-Reviewed Original Research